OBiO Tech(688238)

Search documents
和元生物(688238) - 2024年年度股东大会会议资料
2025-04-25 12:09
股票简称:和元生物 股票代码:688238 2024 年年度股东大会 会议资料 和元生物技术(上海)股份有限公司 OBiO Technology (Shanghai) Corp., Ltd. 2025 年 5 月 和元生物技术(上海)股份有限公司 2024 年年度股东大会会议资料 和元生物技术(上海)股份有限公司 2024 年年度股东大会会议资料目录 | 2024 年年度股东大会会议须知 | 2 | | --- | --- | | 2024 年年度股东大会会议议程 | 4 | | 2024 年年度股东大会会议议案 | 6 | | 议案一、《关于<2024 | 年年度报告及摘要>的议案》 7 | | 议案二、《关于<2024 | 年度董事会工作报告>的议案》 8 | | 议案三、《关于<2024 | 年度监事会工作报告>的议案》 9 | | 议案四、《关于<2024 | 年度财务决算报告>的议案》 10 | | 议案五、《关于<2025 | 年度财务预算报告>的议案》 11 | | 议案六、《关于<2024 | 年度利润分配方案>的议案》 12 | | 议案七、《关于续聘 2025 | 年度审计机构的议案》 1 ...
和元生物一季度业绩下滑,需关注现金流与应收账款
Zheng Quan Zhi Xing· 2025-04-24 22:37
近期和元生物(688238)发布2025年一季报,证券之星财报模型分析如下: 经营概况 近期,和元生物(688238)发布了2025年一季报。报告显示,公司一季度营业总收入为5284.77万元,同比 下降11.29%;归母净利润为-5947.73万元,同比下降41.04%;扣非净利润为-5959.27万元,同比下降 27.17%。 收入构成分析 从主营收入构成来看,细胞和基因治疗CRO业务收入为1,986.40万元,同比增长10.59%,保持稳定增 长;细胞和基因治疗CDMO业务收入为2,761.31万元,同比下降27.74%,主要由于报告期内在执行 CDMO订单的类型及不同CDMO项目推进情况的影响;其他主营业务收入为535.51万元,同比增长 60.26%。 财务指标分析 毛利率与净利率 一季度毛利率为-36.44%,同比减少73.17%;净利率为-112.61%,同比减少58.6%。这表明公司在成本控 制方面面临较大挑战。 三费分析 销售费用、管理费用、财务费用总计2932.12万元,三费占营收比为55.48%,同比增加8.34%。较高的三 费占比进一步压缩了公司的盈利空间。 现金流与负债 一季度每股经 ...
和元生物技术(上海)股份有限公司 2025年第一季度报告
Zheng Quan Ri Bao· 2025-04-23 22:55
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:688238 证券简称:和元生物 重要内容提示 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位:元 币种:人民币 注:财政部于2024年3月发布的《企业会计准则应用指南汇编2024》第十二章"股份支付"明确,股份支 付交易按受益对象确认成本费用。公司根据变更后的会计政策进行追溯调整,追溯调整了上年同期相应 数据。 (二) 非经常性损益项目和金额 √适用 □不适用 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假 记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的,以及将《公 ...
和元生物(688238) - 国泰海通证券股份有限公司关于和元生物技术(上海)股份有限公司2024年度持续督导工作现场检查报告
2025-04-23 10:02
国泰海通证券股份有限公司 关于和元生物技术(上海)股份有限公司 2024 年度持续督导工作现场检查报告 上海证券交易所: 国泰海通证券股份有限公司(以下简称"国泰海通"、"保荐人")作为和元 生物技术(上海)股份有限公司(以下简称"和元生物"或"公司")首次公开 发行股票并在科创板上市的保荐人,根据《中华人民共和国公司法》《中华人民 共和国证券法》《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股 票上市规则》(以下简称"《上市规则》")和《上海证券交易所上市公司自律监管 指引第 11 号——持续督导》等有关法律法规的规定,对公司 2024 年度(以下简 称"本持续督导期间")的规范运作情况进行了现场检查,现就现场检查的有关 情况报告如下: 一、本次现场检查的基本情况 陈恒瑞、张子慧 (三)现场检查时间 2025 年 4 月 10 日至 2025 年 4 月 17 日 (四)现场检查人员 陈恒瑞、张俊鑫 (五)现场检查内容 1 (一)保荐人 国泰海通证券股份有限公司 (二)保荐代表人 现场检查人员对本持续督导期内发行人公司治理及内部控制、信息披露、独 立性、与关联方的资金往来、募集资金使用情况、关联交 ...
和元生物(688238) - 2025 Q1 - 季度财报
2025-04-23 09:55
Financial Performance - The company's revenue for Q1 2025 was ¥52,847,732.33, representing a decrease of 11.29% compared to ¥59,574,128.09 in the same period last year[3] - The net profit attributable to shareholders was -¥59,477,301.44, an increase in loss compared to -¥42,170,292.32 in the previous year[3] - The net cash flow from operating activities was -¥61,413,681.55, slightly improved from -¥62,542,304.19 in the previous year[3] - The weighted average return on equity was -3.48%, a decrease of 1.39 percentage points from -2.09%[3] - The company experienced a decline in revenue primarily due to decreased income from its cell and gene therapy CDMO business[6] - The company achieved a total revenue of RMB 52.85 million, a decrease of 11.29% compared to the same period last year[11] - The revenue from cell and gene therapy CRO business was RMB 19.86 million, an increase of 10.59% year-on-year, indicating stable growth[11] - The revenue from cell and gene therapy CDMO business was RMB 27.61 million, a decrease of 27.74% year-on-year, primarily due to the types of CDMO orders executed during the reporting period[11] - New CDMO orders exceeded RMB 28 million during the reporting period, with the company assisting clients in obtaining 2 IND approvals in the US and China[11] - Net loss for Q1 2025 was CNY 59,510,258.38, compared to a net loss of CNY 42,298,770.28 in Q1 2024, indicating an increase in losses of 40.6%[20] - The net profit attributable to shareholders of the parent company for Q1 2025 was CNY -59,477,301.44, compared to CNY -42,170,292.32 in Q1 2024, representing a 40.9% increase in losses[21] - Basic and diluted earnings per share for Q1 2025 were both CNY -0.092, compared to CNY -0.066 in Q1 2024[21] Research and Development - The total R&D investment was ¥10,820,956.46, down 23.00% from ¥14,053,882.62 year-on-year, with R&D expenses accounting for 20.48% of revenue[4] - The company plans to optimize its R&D personnel structure and focus on core projects, leading to reduced R&D spending[6] - Research and development expenses for Q1 2025 were CNY 10,820,956.46, down from CNY 14,053,882.62 in Q1 2024, a reduction of 23.5%[20] - The company’s R&D expenses for Q1 2025 were ¥2,257,223.97, down from ¥4,154,358.16 in Q1 2024, a reduction of 45.38%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,194,350,719.20, a decrease of 3.96% from ¥2,284,740,741.02 at the end of the previous year[4] - The total assets of the company as of March 31, 2025, were RMB 2.19 billion, a decrease from RMB 2.28 billion at the end of 2024[16] - Total liabilities as of the end of the reporting period were CNY 571,887,808.95, an increase from CNY 545,193,225.79 at the end of the previous period[17] - The total equity attributable to shareholders of the parent company was CNY 1,622,740,580.83, down from CNY 1,739,792,228.87, a decrease of 6.7%[17] - The total current assets increased to ¥1,055,705,282.14 as of March 31, 2025, compared to ¥1,022,034,773.67 at the end of 2024, reflecting a growth of 3.63%[28] - The total liabilities increased to ¥285,590,552.30 as of March 31, 2025, compared to ¥185,513,971.89 at the end of 2024, indicating a growth of 54.00%[29] Cash Flow and Financing - As of March 31, 2025, the company had cash and cash equivalents of RMB 360.04 million, down from RMB 439.44 million at the end of 2024[15] - The cash and cash equivalents at the end of the period were ¥355,486,612.35, down from ¥562,880,278.98 at the end of the previous period, representing a decrease of 36.83%[25] - The company received cash from investment activities totaling ¥90,580,816.32, significantly higher than ¥28,685,449.94 in the previous period[25] - The cash outflow from investment activities was ¥150,952,902.19, an increase from ¥112,499,033.84 in the previous period[25] - The cash flow from financing activities in Q1 2025 was 49,471,025.59 RMB, compared to 58,191,094.73 RMB in Q1 2024, indicating a decrease of about 15%[34] - The company paid 71,233,500.00 RMB in debt repayments during Q1 2025, a significant increase from 1,233,500.00 RMB in Q1 2024[34] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,799[8] - The largest shareholder, Pan Oudong, holds 18.92% of the shares, totaling 122,805,540 shares[8] Other Developments - The company completed a share buyback of 18,726,690 shares for a total payment of RMB 99.94 million[14] - The company registered 3 new domestic trademarks and applied for 2 invention patents and 6 utility model patents during the reporting period[12] - The company’s long-term equity investments amounted to RMB 66.61 million as of March 31, 2025, slightly up from RMB 66.34 million at the end of 2024[16] - The company’s short-term borrowings increased significantly to RMB 180.75 million from RMB 70.05 million at the end of 2024[16]
和元生物:2025一季报净利润-0.59亿 同比下降40.48%
Tong Hua Shun Cai Bao· 2025-04-23 09:40
Group 1 - The article discusses financial performance metrics for various companies, highlighting significant changes in their financial figures from 2023 to 2025 [1][2] - A notable decline in certain metrics is observed, such as a 39.39% decrease in one company's figure from 2023 to 2024 [1] - The overall financial landscape shows a mixed performance, with some companies experiencing substantial losses, such as a 407.69% increase in negative figures for one entity [1] Group 2 - The total revenue for a specific sector is reported at 24,330.32 million, reflecting a 37.95% increase compared to previous figures [2] - Individual company performances vary, with one company generating 12,280.55 million, representing a 19.15% increase [2] - Some companies report negative changes, such as a significant drop of 495.00 million in one category, indicating potential challenges within that segment [2]
和元生物:2025年第一季度净亏损5947.73万元
news flash· 2025-04-23 09:36
和元生物公告,2025年第一季度营收为5284.77万元,同比下降11.29%;净亏损5947.73万元,去年同期 净亏损4217.03万元。 ...
【私募调研记录】混沌道然资产调研和元生物
Zheng Quan Zhi Xing· 2025-04-23 00:12
Group 1 - The core viewpoint is that He Yuan Bio is experiencing sustained policy support in the cell and gene therapy (CGT) sector, with indications expanding from tumors to multiple areas, despite a cautious investment environment [1] - The company's CDMO business is affected by a slowdown in investment, leading to short-term fluctuations in gross margin, but the long-term market potential remains significant, with gross margins expected to gradually recover [1] - The CRO business is showing steady growth, with an 8.02% increase in sales revenue and an expanding customer base, while actively exploring overseas markets [1] Group 2 - In the fourth quarter, sales and management expenses increased while R&D expenses decreased, with plans for multiple quality improvement measures in 2025 [1] - He Yuan Bio has established a wholly-owned subsidiary, He Yuan He Mei, in the field of regenerative medicine to achieve large-scale cell production and expand its CRO/CDMO full industry chain services [1] - The company has signed new orders exceeding 270 million, and the GMP capacity utilization rate at the Lingang industrial base continues to improve [1] Group 3 - The company aims to optimize its business model centered around underlying technology, expand into international markets, and strengthen strategic partnerships, aspiring to become a comprehensive service platform in the fields of cell gene therapy and regenerative medicine, with a focus on both domestic and global markets [1]
和元生物:4月18日召开业绩说明会,国泰海通证券、鹏华基金等多家机构参与
Zheng Quan Zhi Xing· 2025-04-22 11:07
证券之星消息,2025年4月22日和元生物(688238)发布公告称公司于2025年4月18日召开业绩说明会,国 泰海通证券、鹏华基金、招商基金、华安基金、银河基金、上银基金、博远基金、招银国际基金、肇万 资产、长见投资、勤远资产、中金公司(601995)、混沌道然资产、保银投资、中信证券、申万宏源证 券(000562)、兴业证券、东方证券、浙商证券(601878)、华西证券(002926)、天风证券 (601162)参与。 具体内容如下: 问:目前国内CGT行业需求和供给的变化情况如何,处于什么阶段,未来景气度恢复情况怎样? 答:从政策方面,国家和各地产业发展继续加大对细胞和基因治疗领域的支持力度,出台一系列政策和 产业支持措施。同时,监管部门出台的一系列指南对于药物开发进一步规范,保障了行业长期健康发 展,促进了创新药对于高水平、高规格的CRO/CDMO需求。从技术和管线进度看,细胞和基因治疗领 域的相关产品正大规模走向临床,适应症从肿瘤领域向包括心血管、神经系统、血液学及自身免疫性疾 病等领域拓展。干细胞再生医学转化应用得到支持和推进,基因治疗商业化进程有里程碑式推进,如 2025年4月份,国内首款腺相 ...
和元生物(688238):细胞与基因治疗CDMO维持向上增长趋势,战略布局再生医学业务
HUAXI Securities· 2025-04-20 07:57
证券研究报告|公司点评报告 [Table_Date] 2025 年 04 月 20 日 [Table_Summary] 事件概述 公司公告 2024 年报:24 全年实现营业收入 2.48 亿元,同比增 长 21.16%、实现归母净利润-3.22 亿元、实现扣非净利润-3.36 亿元。 分析判断: ► 细胞与基因治疗 CDMO 维持向上增长趋势,战略布局 再生医学业务 公司 24 年实现收入 2.48 亿元,同比增长 21.16%,其中细胞与基 因治疗 CDMO 业务实现收入 1.35 亿元,同比增长 26.12%、细胞与 基因治疗 CRO 业务实现收入 0.86 亿元,同比增长 8.02%,核心业 务延续向上增长趋势。公司 23 年实现归母净利润-3.22 亿元,相 对 23 年的-1.13 亿元呈现放大亏损,我们判断主要受竞争加剧导 致项目价格下降、临港产业基地投产引起运营成本增加以及周浦 医学园区搬迁导致的转移成本和损失等。展望未来,公司继续坚 定布局一体化的细胞与基因治疗 CRO+CDMO 业务,同时战略性布 局再生医学业务,且考虑到未来投融资景气度有望面临进一步改 善,我们判断公司业绩端有望在未来几 ...